Entry |
|
Name |
Regadenoson (INN); Regadenoson anhydrous |
Product |
|
Generic |
|
Formula |
C15H18N8O5
|
Exact mass |
390.1400
|
Mol weight |
390.35
|
Structure |

|
Remark |
Product (DG03262): | D12568<US> D05711<US> |
|
Efficacy |
Vasodilator (coronary), Adenosine A2a receptor agonist |
Target |
|
Pathway |
hsa04080 | Neuroactive ligand-receptor interaction |
hsa04270 | Vascular smooth muscle contraction |
|
Brite |
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
C CARDIOVASCULAR SYSTEM
C01 CARDIAC THERAPY
C01E OTHER CARDIAC PREPARATIONS
C01EB Other cardiac preparations
C01EB21 Regadenoson
D12568 Regadenoson (INN) <US>
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Rhodopsin family
Adenosine
ADORA2A
D12568 Regadenoson (INN) <US>
|
Other DBs |
|
LinkDB |
|
KCF data |
ATOM 28
1 C1y C 15.6260 -13.8041
2 C1y C 16.9574 -13.8041
3 C1y C 17.4479 -12.4728
4 O2x O 16.2567 -11.6319
5 C1y C 15.1355 -12.4728
6 O1a O 14.9253 -14.9954
7 O1a O 17.6581 -14.9954
8 N4y N 18.7092 -12.0523
9 C1b C 13.8742 -12.0523
10 O1a O 12.8231 -12.9633
11 C8y C 19.7602 -12.9633
12 C8y C 20.9515 -12.3326
13 N5x N 20.6712 -10.9312
14 C8x C 19.3398 -10.7911
15 N5x N 19.7602 -14.3647
16 C8y C 20.9515 -15.0654
17 N5x N 22.2128 -14.4348
18 C8y C 22.1427 -13.0334
19 N1a N 23.4040 -12.2626
20 N4y N 20.9515 -16.5369
21 N5x N 19.8303 -17.3778
22 C8x C 20.3208 -18.7092
23 C8y C 21.7223 -18.7092
24 C8x C 22.1427 -17.3077
25 O5a O 21.7223 -21.1617
26 C5a C 22.4230 -19.9705
27 N1b N 23.8244 -19.9705
28 C1a C 24.5251 -21.1617
BOND 31
1 1 2 1
2 2 3 1
3 3 4 1
4 4 5 1
5 1 5 1
6 1 6 1 #Down
7 2 7 1 #Down
8 3 8 1 #Up
9 5 9 1 #Up
10 9 10 1
11 8 11 1
12 11 12 1
13 12 13 1
14 13 14 2
15 8 14 1
16 11 15 2
17 15 16 1
18 16 17 2
19 17 18 1
20 12 18 2
21 18 19 1
22 16 20 1
23 20 21 1
24 21 22 2
25 22 23 1
26 23 24 2
27 20 24 1
28 25 26 2
29 23 26 1
30 26 27 1
31 27 28 1
|